Cite
HARVARD Citation
Matsubara, N. et al. (2023). Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma. Cancer medicine. pp. 2761-2771. [Online].